Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
JAAD Int. 2021 Nov 9:6:3-5.
doi: 10.1016/j.jdin.2021.09.007.
eCollection 2022 Mar.
1 Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
2 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
3 Michael G. DeGroote School of Medicine, Faculty of Medicine, Hamilton, Ontario, Canada.
4 Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
5 Division of Dermatology, Department of Medicine, and Divisions of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; and Probity Medical Research, Calgary, Alberta, Canada.
6 Dermatrials Research Inc., Hamilton, Ontario, Canada.
7 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
8 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
9 Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
10 Probity Medical Research Inc., Waterloo, Ontario, Canada.